Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:03:16 EDT Sat 15 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:INMB from 2024-03-15 to 2025-03-14 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-02-12 07:00U:INMBNews ReleaseINmune Bio Opens Phase II in High Dose Cohort of INKmune(TM) Trial in Prostate Cancer
2025-02-10 07:00U:INMBNews ReleaseINmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
2025-01-28 08:00U:INMBNews ReleaseINmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
2024-12-10 08:00U:INMBNews ReleaseINmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
2024-12-04 09:00U:INMBNews ReleaseOmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
2024-12-04 09:00U:INMBNews ReleaseOmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
2024-11-13 09:00U:INMBNews ReleaseINmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
2024-10-31 16:06U:INMBNews ReleaseINmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
2024-10-28 08:00U:INMBNews ReleaseINmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
2024-10-24 15:03U:INMBNews ReleaseINmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro(TM) Promotes Remyelination
2024-10-24 09:30U:INMBNews ReleaseINmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
2024-10-11 08:30U:INMBNews ReleaseINmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
2024-09-30 08:00U:INMBNews ReleaseINmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
2024-09-26 08:00U:INMBNews ReleaseINKmune(TM) Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
2024-09-17 08:30U:INMBNews ReleaseINmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
2024-09-13 08:30U:INMBNews ReleaseINmune Bio Announces $13.0 Million Registered Direct Offering
2024-09-03 09:00U:INMBNews ReleaseINmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
2024-08-01 16:06U:INMBNews ReleaseINmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
2024-07-29 09:00U:INMBNews ReleaseINmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro(TM) on Proteins that Regulation Synapses in Alzheimer's Patients
2024-07-25 08:00U:INMBNews ReleaseINmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
2024-07-23 08:45U:INMBNews ReleaseINmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune(TM) in the Journal for ImmunoTherapy of Cancer
2024-06-27 08:00U:INMBNews ReleaseINmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial
2024-05-30 08:00U:INMBNews ReleaseINmune Bio Inc. to Join Russell 3000(TM) Index
2024-05-09 16:06U:INMBNews ReleaseINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
2024-05-07 08:00U:INMBNews ReleaseINmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
2024-04-30 08:00U:INMBNews ReleaseINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro(TM) Under Compassionate Use for Over Three Years
2024-04-29 08:00U:INMBNews ReleaseINmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune(TM) Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
2024-04-25 09:00U:INMBNews ReleaseINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-04-23 08:00U:INMBNews ReleaseINmune Bio Inc. Announces 24-Month Stability Validation of XPro(TM) for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
2024-04-22 08:00U:INMBNews ReleaseINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
2024-04-08 08:00U:INMBNews ReleaseINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
2024-03-28 16:02U:INMBNews ReleaseINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
2024-03-26 16:01U:INMBNews ReleaseINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28